Ruba Mshref, Ahmad Alkheder, Nasser Alia, Rawad Salama, Mariana Naief Sharaf Aldeen, Raouf Salem Seif Eddin
{"title":"Isolated Unilateral Temporalis Muscle Hypertrophy: Comprehensive Literature Review.","authors":"Ruba Mshref, Ahmad Alkheder, Nasser Alia, Rawad Salama, Mariana Naief Sharaf Aldeen, Raouf Salem Seif Eddin","doi":"10.1177/01455613251342858","DOIUrl":null,"url":null,"abstract":"<p><p>Isolated unilateral temporalis muscle hypertrophy (IUTMH) is a rare clinical entity, with fewer than 20 cases reported globally. This case report and literature review aimed to expand the understanding of its diagnosis, management, and outcomes. A 44-year-old Arab Asian woman presented with a 12 month history of progressive left temporal swelling and pain during mastication. Clinical examination revealed a firm, non-tender mass. Imaging [computed tomography (CT) and ultrasonography] confirmed isolated left temporalis muscle hypertrophy without neoplastic or inflammatory features. Botulinum toxin type A (Btx A, 25 U) injection led to symptom improvement and partial muscle reduction at 3 month follow-up. A literature review of 16 published cases (including ours) demonstrated a slight female predominance (10/16), variable symptom profiles (painless swelling to masticatory dysfunction), and diverse management strategies. Minimally-invasive Btx A achieved favorable outcomes in 6/16 cases, with lower doses (25 U) showing efficacy comparable with higher doses. Surgical intervention, although effective, was associated with recurrence in 1 case. Diagnostic reliance on imaging (CT/magnetic resonance imaging) and histology (when performed) confirmed hypertrophy without malignancy. While bruxism and stress were implicated in some cases, 7/16 lacked identifiable triggers, suggesting multifactorial etiology. Long-term follow-up data remain limited, underscoring the need for vigilant monitoring. This case reinforces Btx A as a primary therapeutic option and highlights the importance of individualized management in IUTMH. Further research is warranted to elucidate pathogenesis and optimize treatment protocols.</p>","PeriodicalId":93984,"journal":{"name":"Ear, nose, & throat journal","volume":" ","pages":"1455613251342858"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ear, nose, & throat journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/01455613251342858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Isolated unilateral temporalis muscle hypertrophy (IUTMH) is a rare clinical entity, with fewer than 20 cases reported globally. This case report and literature review aimed to expand the understanding of its diagnosis, management, and outcomes. A 44-year-old Arab Asian woman presented with a 12 month history of progressive left temporal swelling and pain during mastication. Clinical examination revealed a firm, non-tender mass. Imaging [computed tomography (CT) and ultrasonography] confirmed isolated left temporalis muscle hypertrophy without neoplastic or inflammatory features. Botulinum toxin type A (Btx A, 25 U) injection led to symptom improvement and partial muscle reduction at 3 month follow-up. A literature review of 16 published cases (including ours) demonstrated a slight female predominance (10/16), variable symptom profiles (painless swelling to masticatory dysfunction), and diverse management strategies. Minimally-invasive Btx A achieved favorable outcomes in 6/16 cases, with lower doses (25 U) showing efficacy comparable with higher doses. Surgical intervention, although effective, was associated with recurrence in 1 case. Diagnostic reliance on imaging (CT/magnetic resonance imaging) and histology (when performed) confirmed hypertrophy without malignancy. While bruxism and stress were implicated in some cases, 7/16 lacked identifiable triggers, suggesting multifactorial etiology. Long-term follow-up data remain limited, underscoring the need for vigilant monitoring. This case reinforces Btx A as a primary therapeutic option and highlights the importance of individualized management in IUTMH. Further research is warranted to elucidate pathogenesis and optimize treatment protocols.